It was a pleasure for us to host Ester Baiget, President and CEO of Novonesis, and Tue Micheelsen, VP and President of North America, at our 21st.BIO Davis office.
During their visit, we showcased our latest advancements in strain engineering, fermentation, and biomanufacturing.
Our production strains, partly based on technology licensed from Novonesis – a global leader in biosolutions and an investor in 21st.BIO – are a testament to our joint R&D expertise.
The techology base licensed from Novonesis has been developed and optimized for large scale production over decades. Our work, built on this strong foundation, has led to strains and fermentation protocols which are powerful production tools to unlock the potential of protein- and peptide-based innovations.
At 21st.BIO, we grant our customers a high-performance platform with optimized fermentation protocols for multiple expression systems. This provides risk-mitigated, high-performance solutions to large-scale bioproduction across various industries.
We continuously expand our portfolio with more and more proteins and peptides serving the nutrition, food, agriculture, biomaterials, and even biomining industries. We work hard to improve titers and optimize processes, ensuring our customers can stay ahead of the market – long term.
We’re very proud to build on the legacy of the Novo Group and Novonesis in particular. Thank you for your visit, Ester and Tue!
